1. ensuring that STD prevention programs establish linkages with correctional facilities, substance use treatment programs, homeless and runaway programs, migrant health programs, and other facilities and programs that serve high-risk populations to ensure appropriate screening, diagnosis and treatment, and follow-up of infected persons and their partners. Such linkages should ensure that all adolescents and adults living in environments where the risk for STDs is high have access to confidential, comprehensive, high-quality STD-related services. In addition, the CDC, in collaboration with other appropriate agencies, should develop STD screening guidelines suitable for use in venues that have not been traditionally targeted by STD screening programs; and
  2. developing and implementing interventions and services for STDs that are (a) focused, sustained, and culturally appropriate; (b) provided by a spectrum of health care professionals, including potential non-health-care professionals such as educators, peers, and community volunteers; (c) delivered through a variety of settings, including nontraditional settings such as substance use treatment centers, mobile clinics, and the streets; and (d) reinforced at multiple points and venues to sustain and maximize effectiveness.
  • Prisons and other detention facilities should provide comprehensive STD-related services, including STD prevention counseling and education, screening, diagnosis and treatment, partner notification and treatment, and methods for reducing unprotected sexual intercourse and drug use among prisoners. Rapid screening and treatment programs for STDs should be developed and implemented. In addition to health agencies, prison administrators should seek assistance and guidance in developing and implementing the above services from correctional systems that have already implemented effective programs to prevent STDs.
  • The National Institutes of Health, the Food and Drug Administration, and the CDC should work with pharmaceutical and biotechnology companies to develop improved STD diagnostic tools (e.g., rapid saliva and urine tests) that are suitable for use in nontraditional health care settings (e.g., prisons, mobile clinics, the streets). Pharmaceutical, biotechnology, and medical device companies should continue to invest in research to develop and improve vaccines, diagnostic tests, antiviral treatments, and mechanical and chemical barrier protection for women and assist in promoting public and health care provider awareness and knowledge of STDs. In addition, such companies should ensure that the cost of existing and new biomedical interventions for STDs are affordable to publicly sponsored STD programs.
  • Strategy 4:

    Ensure Access To Services

    Strategy 4 is to ensure access to and quality of essential clinical services for STDs. As demonstrated in Chapter 5, both public and private sector clinical



    The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
    Copyright © National Academy of Sciences. All rights reserved.
    Terms of Use and Privacy Statement